The Ministry of Health has launched the public hearing process for the future Reference Price Order (OPR) for 2026. From its official publication, interested parties will have a period of 15 business days to submit any comments or observations they consider appropriate.
Key points
- Application of the CIPM’s new powers: The main new feature this year is the inclusion of a specific annex for medicinal products that, by decision of the Interministerial Committee on Medicine Prices (CIPM), are exempted from the Reference Price System or are subject to increase coefficients.
- This measure is the direct result of the amendment to Article 98 of the Royal Legislative Decree 1/2015, introduced by the Law creating the Public Health Agency —Law 7/2025—.
- The aim is to ensure the supply and economic viability of critical medicines or medicines at risk of shortage.
- Configuration of groups: The draft provides for the creation of 26 new groups, distributed as follows: 14 for community pharmacies, 11 in the hospital setting, and 1 for clinical packs. At the same time, it proposes the removal of 19 existing groups.
This process represents a key opportunity for companies in the sector to assess the impact on their portfolios and submit their observations to the Directorate-General for the Common Portfolio of National Health System Services and Pharmacy.
If you need advice on how this new scenario affects your presentations or require support in preparing submissions, please contact our Life Sciences team.
May 15, 2026
Don’t miss our content
Subscribe